Posted by Michael Wonder on 14 Oct 2020
Scotland backs two myeloma drugs turned down by NICE in England
14 October 2020 - A north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium backed NHS use of two drugs previously turned down by NICE in England.
The SMC has accepted use by NHS Scotland of Bristol-Myers Squibb’s Revlimid (lenalidomide) and Amgen’s Kyprolis (carfilzomib) as first- and second-line therapies respectively for myeloma, a form of blood cancer.
